Combined MEK and PI3K/p110β Inhibition as a Novel Targeted Therapy for Malignant Mesothelioma Displaying Sarcomatoid Features

Citation
Marqués, M., Tranchant, R., Risa-Ebrí, B., Suárez-Solís, M. L., Fernández, L. C., Carrillo-de-Santa-Pau, E., del Pozo, N., Martínez de Villarreal, J., Meiller, C., Allory, Y., Blum, Y., Pirker, C., Hegedus, B., Barry, S. T., Carnero, A., Berger, W., Jean, D., & Real, F. X. (2020). Combined MEK and PI3K/p110β Inhibition as a Novel Targeted Therapy for Malignant Mesothelioma Displaying Sarcomatoid Features. Cancer Research, 80(4), 843–856. https://doi.org/10.1158/0008-5472.can-19-1633
DOI:
DOI: 10.1158/0008-5472.CAN-19-1633
Year of publication:
2020